N/A N=90 Randomized Double-blind Treatment

Effects of CPAP on Visceral Fat Thickness

Obstructive Sleep Apnea

Bottom Line

View on ClinicalTrials.gov: NCT01828281 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2015

Primary outcome: Primary: Mesenteric Fat Thickness — 0.96; 0.94 cm

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: CPAP (Device)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: Chinese University of Hong Kong
Primary completion: Oct 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Mesenteric Fat Thickness	0.96; 0.94	—
SECONDARY Mean Changes in Adiponectin Over 3 Months	23.63; 29.78	—

Summary

We hypothesize that patients with untreated OSAS will have more visceral fat, fatty liver and increased carotid artery thickness whereas treatment with CPAP may reduce the mesenteric and liver fat, plasma lipids, carotid artery thickness.

Eligibility Criteria

Inclusion Criteria

symptomatic patients with OSA of apnea hypopnea index (AHI) >= 5/hr

Exclusion Criteria

Recent or past history of myocardial infarction/stroke/heart failure, unstable angina, underlying malignancy,
patients with clinical features of any active infection
those who require urgent CPAP treatment because of associated respiratory failure or to prevent job loss through excessive daytime sleepiness (eg professional drivers, those handling dangerous machinery)
moderate to severe valvular heart disease, cardiomyopathy, and previous diagnosis of OSA and/or previous use of CPAP therapy.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01828281). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.